- South Korea
- /
- Personal Products
- /
- KOSDAQ:A241710
Is Cosmecca Korea Co., Ltd. (KOSDAQ:241710) Trading At A 44% Discount?
Key Insights
- The projected fair value for Cosmecca Korea is ₩70,571 based on 2 Stage Free Cash Flow to Equity
- Current share price of ₩39,300 suggests Cosmecca Korea is potentially 44% undervalued
- Our fair value estimate is 25% higher than Cosmecca Korea's analyst price target of ₩56,500
Today we will run through one way of estimating the intrinsic value of Cosmecca Korea Co., Ltd. (KOSDAQ:241710) by estimating the company's future cash flows and discounting them to their present value. Our analysis will employ the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex.
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
See our latest analysis for Cosmecca Korea
The Calculation
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) estimate
2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
Levered FCF (₩, Millions) | ₩33.3b | ₩39.0b | ₩43.2b | ₩46.9b | ₩49.9b | ₩52.6b | ₩54.9b | ₩57.0b | ₩59.0b | ₩60.8b |
Growth Rate Estimate Source | Analyst x2 | Analyst x3 | Est @ 10.88% | Est @ 8.34% | Est @ 6.56% | Est @ 5.32% | Est @ 4.44% | Est @ 3.83% | Est @ 3.41% | Est @ 3.11% |
Present Value (₩, Millions) Discounted @ 8.6% | ₩30.7k | ₩33.1k | ₩33.8k | ₩33.7k | ₩33.1k | ₩32.1k | ₩30.9k | ₩29.5k | ₩28.1k | ₩26.7k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = ₩311b
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.4%. We discount the terminal cash flows to today's value at a cost of equity of 8.6%.
Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = ₩61b× (1 + 2.4%) ÷ (8.6%– 2.4%) = ₩1.0t
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= ₩1.0t÷ ( 1 + 8.6%)10= ₩442b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is ₩754b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of ₩39k, the company appears quite undervalued at a 44% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
Important Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Cosmecca Korea as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.6%, which is based on a levered beta of 1.161. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Cosmecca Korea
- Earnings growth over the past year exceeded the industry.
- Debt is not viewed as a risk.
- No major weaknesses identified for A241710.
- Annual revenue is forecast to grow faster than the South Korean market.
- Good value based on P/E ratio and estimated fair value.
- Annual earnings are forecast to grow slower than the South Korean market.
Looking Ahead:
Whilst important, the DCF calculation is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Can we work out why the company is trading at a discount to intrinsic value? For Cosmecca Korea, we've put together three essential items you should explore:
- Financial Health: Does A241710 have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does A241710's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every South Korean stock every day, so if you want to find the intrinsic value of any other stock just search here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A241710
Cosmecca Korea
Engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally.
Flawless balance sheet with solid track record.